Korean Health Screening-Based Metabolic Dysfunction-Associated Steatotic Liver Disease Registry

Condition(s) studied

Study summary

The goal of this observational study is to establish a multi-center registry to better understand Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) using health screening data from Korean hospitals. MASLD is a liver condition where excess fat builds up in the liver and is closely linked to metabolic health problems like high blood pressure, diabetes, and obesity.

The main questions this study aims to answer are:

* What are the characteristics of people with MASLD?
* How is MASLD related to other health conditions, especially heart and blood vessel diseases?
* What factors might help identify MASLD early?

Researchers will compare two groups of people:

* People who have MASLD
* People who don't have MASLD (control group)

This study will look at health screening records from 2020 to 2023 from six Korean hospitals. The research team will collect and analyze:

* Basic health information (age, gender, weight, height, waist size)
* Lifestyle habits (drinking, smoking, exercise, eating habits)
* Medical conditions (high blood pressure, diabetes, high cholesterol)
* Results from medical tests including:

Liver ultrasound and Fibroscan results Heart CT scans Blood vessel ultrasound Blood test results Other health screening results

Participants in this study will not need to do anything new. The researchers will only look at information that was already collected during regular health screenings. All personal information will be protected and kept private.

This research could help doctors:

* Better understand who is at risk for MASLD
* Find MASLD earlier
* Develop better ways to prevent and treat MASLD
* Understand how MASLD is connected to other health problems

The study will take place over 3 years and includes adults age 19 and older who had health screenings at participating Korean hospitals. People who drink large amounts of alcohol or have other liver diseases will not be included in the study.

By learning more about MASLD through this registry study, researchers hope to improve healthcare for people with or at risk for this liver condition.

Eligibility

Primary outcome measure(s)

• Incidence Rate of Major Adverse Cardiovascular Events (MACE) — within 3 years
  MACE was defined as the composite endpoint of all-cause death, myocardial infarction, or stroke.

Trial sites (5)

More Korea University trials in South Korea

Other trials for the same condition